Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder

Xiao-Fei Zhang, Lei Wu, Dong-Jun Wan, Ruo-Zhuo Liu, Zhao Dong, Min Chen, Sheng-Yuan Yu Department of Neurology, Chinese PLA General Hospital, Beijing, People’s Republic of China Purpose: Vilazodone is a novel serotonin (5-HT)-reuptake inhibitor and 5-HT1A partial agonist that was recentl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zhang XF, Wu L, Wan DJ, Liu RZ, Dong Z, Chen M, Yu SY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/cd36f614b882465a951a3c4cab6b4084
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd36f614b882465a951a3c4cab6b4084
record_format	dspace
spelling	oai:doaj.org-article:cd36f614b882465a951a3c4cab6b40842021-12-02T02:10:17ZEvaluation of the efficacy and safety of vilazodone for treating major depressive disorder1178-2021https://doaj.org/article/cd36f614b882465a951a3c4cab6b40842015-08-01T00:00:00Zhttp://www.dovepress.com/evaluation-of-the-efficacy-and-safety-of-vilazodone-for-treating-major-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Xiao-Fei Zhang, Lei Wu, Dong-Jun Wan, Ruo-Zhuo Liu, Zhao Dong, Min Chen, Sheng-Yuan Yu Department of Neurology, Chinese PLA General Hospital, Beijing, People’s Republic of China Purpose: Vilazodone is a novel serotonin (5-HT)-reuptake inhibitor and 5-HT1A partial agonist that was recently developed for the treatment of major depressive disorder (MDD). We conducted a meta-analysis and systematic review to better evaluate the efficacy and safety of vilazodone. Materials and methods: We performed a thorough literature search to identify all randomized double-blind placebo-controlled trials that were designed to investigate the efficacy of vilazodone for the treatment of MDD, and that were published in electronic databases, including Medline, Embase, and the Cochrane Central Register of Controlled Trials. A manual search was also conducted to investigate the relevant references of the retrieved studies. Subsequently, we conducted a meta-analysis and systematic literature review. Results: A total of five randomized controlled trials were finally included, involving 1,200 patients with vilazodone and 1,193 patients with placebo. The primary efficacy end point of the Montgomery–Åsberg Depression Rating Scale (standardized mean difference -3.58, 95% confidence interval -4.59 to -2.56; P<0.00001), and the key secondary efficacy end points (Clinical Global Impression - Severity scale, Clinical Global Impression - Improvement scale, and Hamilton Anxiety Rating Scale) indicated that vilazodone was more effective than placebo. Most common adverse events, including diarrhea and nausea, were evaluated, and safety assessments indicated that vilazodone was well tolerated (diarrhea odds ratio 3.54, 95% confidence interval 2.81–4.45; P<0.00001; nausea odds ratio 3.85, 95% confidence interval 3.00–4.96; P<0.00001; discontinuations due to adverse events odds ratio 2.71, 95% confidence interval 1.81–4.05; P<0.00001). Conclusion: Our findings indicate that the novel antidepressant vilazodone is effective and safe for MDD, with a low occurrence of side effects. It offers promise as an effective oral drug for the treatment of MDD, with a balance of efficacy and tolerability. Keywords: vilazodone, major depression, systematic review, antidepressant, randomized controlled trialZhang XFWu LWan DJLiu RZDong ZChen MYu SYDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 1957-1965 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Zhang XF Wu L Wan DJ Liu RZ Dong Z Chen M Yu SY Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
description	Xiao-Fei Zhang, Lei Wu, Dong-Jun Wan, Ruo-Zhuo Liu, Zhao Dong, Min Chen, Sheng-Yuan Yu Department of Neurology, Chinese PLA General Hospital, Beijing, People’s Republic of China Purpose: Vilazodone is a novel serotonin (5-HT)-reuptake inhibitor and 5-HT1A partial agonist that was recently developed for the treatment of major depressive disorder (MDD). We conducted a meta-analysis and systematic review to better evaluate the efficacy and safety of vilazodone. Materials and methods: We performed a thorough literature search to identify all randomized double-blind placebo-controlled trials that were designed to investigate the efficacy of vilazodone for the treatment of MDD, and that were published in electronic databases, including Medline, Embase, and the Cochrane Central Register of Controlled Trials. A manual search was also conducted to investigate the relevant references of the retrieved studies. Subsequently, we conducted a meta-analysis and systematic literature review. Results: A total of five randomized controlled trials were finally included, involving 1,200 patients with vilazodone and 1,193 patients with placebo. The primary efficacy end point of the Montgomery–Åsberg Depression Rating Scale (standardized mean difference -3.58, 95% confidence interval -4.59 to -2.56; P<0.00001), and the key secondary efficacy end points (Clinical Global Impression - Severity scale, Clinical Global Impression - Improvement scale, and Hamilton Anxiety Rating Scale) indicated that vilazodone was more effective than placebo. Most common adverse events, including diarrhea and nausea, were evaluated, and safety assessments indicated that vilazodone was well tolerated (diarrhea odds ratio 3.54, 95% confidence interval 2.81–4.45; P<0.00001; nausea odds ratio 3.85, 95% confidence interval 3.00–4.96; P<0.00001; discontinuations due to adverse events odds ratio 2.71, 95% confidence interval 1.81–4.05; P<0.00001). Conclusion: Our findings indicate that the novel antidepressant vilazodone is effective and safe for MDD, with a low occurrence of side effects. It offers promise as an effective oral drug for the treatment of MDD, with a balance of efficacy and tolerability. Keywords: vilazodone, major depression, systematic review, antidepressant, randomized controlled trial
format	article
author	Zhang XF Wu L Wan DJ Liu RZ Dong Z Chen M Yu SY
author_facet	Zhang XF Wu L Wan DJ Liu RZ Dong Z Chen M Yu SY
author_sort	Zhang XF
title	Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
title_short	Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
title_full	Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
title_fullStr	Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
title_full_unstemmed	Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
title_sort	evaluation of the efficacy and safety of vilazodone for treating major depressive disorder
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/cd36f614b882465a951a3c4cab6b4084
work_keys_str_mv	AT zhangxf evaluationoftheefficacyandsafetyofvilazodonefortreatingmajordepressivedisorder AT wul evaluationoftheefficacyandsafetyofvilazodonefortreatingmajordepressivedisorder AT wandj evaluationoftheefficacyandsafetyofvilazodonefortreatingmajordepressivedisorder AT liurz evaluationoftheefficacyandsafetyofvilazodonefortreatingmajordepressivedisorder AT dongz evaluationoftheefficacyandsafetyofvilazodonefortreatingmajordepressivedisorder AT chenm evaluationoftheefficacyandsafetyofvilazodonefortreatingmajordepressivedisorder AT yusy evaluationoftheefficacyandsafetyofvilazodonefortreatingmajordepressivedisorder
_version_	1718402678808117248

Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder

Ejemplares similares